Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients

Neuropharmacology

Volumn 58, Issue 2, 2010, Pages 452-456

  Kishi, Taro ^a   Tsunoka, Tomoko ^a   Ikeda, Masashi ^a,b   Kitajima, Tsuyoshi ^a   Kawashima, Kunihiro ^a   Okochi, Tomo ^a   Okumura, Takenori ^a   Yamanouchi, Yoshio ^a   Kinoshita, Yoko ^a   Ujike, Hiroshi ^c,d   Inada, Toshiya ^c,e   Yamada, Mitsuhiko ^c,f   Uchimura, Naohisa ^c,g   Sora, Ichiro ^c,h   Iyo, Masaomi ^c,i   Ozaki, Norio ^c,j   Iwata, Nakao ^a,c  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Japanese Genetics Initiative for Drug Abuse ^*  (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e SEIWA HOSPITAL   (Japan)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Functional SNP; Methamphetamine induced psychosis; Serotonin 1A receptor gene (HTR1A); Tagging SNP

Indexed keywords

METHAMPHETAMINE; SEROTONIN 1A RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AMPHETAMINE-RELATED DISORDERS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; JAPAN; LINKAGE DISEQUILIBRIUM; MALE; METHAMPHETAMINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTOR, SEROTONIN, 5-HT1A; SEQUENCE ANALYSIS, DNA;

EID: 72049102119     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.09.006     Document Type: Article

References (52)

1. Albert P.R., Lembo P., Storring J.M., Charest A., and Saucier C. The 5-HT1A receptor: signaling, desensitization, and gene transcription. Neuropsychopharmacology 14 (1996) 19-25
2. Albert P.R., and Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist 10 (2004) 575-593
3. Anttila S., Huuhka K., Huuhka M., Rontu R., Hurme M., Leinonen E., and Lehtimaki T. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J. Neural Transm. 114 (2007) 1065-1068
4. Arias B., Catalan R., Gasto C., Gutierrez B., and Fananas L. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J. Psychopharmacol. 19 (2005) 166-172
5. Aznar S., Qian Z., Shah R., Rahbek B., and Knudsen G.M. The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res. 959 (2003) 58-67
6. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
7. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
8. Bousman C.A., Glatt S.J., Everall I.P., and Tsuang M.T. Genetic association studies of methamphetamine use disorders: a systematic review and synthesis. Am. J. Med. Genet. B Neuropsychiatr. Genet (2009)
9. Brezo J., Bureau A., Merette C., Jomphe V., Barker E.D., Vitaro F., Hebert M., Carbonneau R., Tremblay R.E., and Turecki G. Differences and similarities in the serotonergic diathesis for suicide attempts and mood disorders: a 22-year longitudinal gene-environment study. Mol. Psychiatry (2009)
10. Burnet P.W., Eastwood S.L., and Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15 (1996) 442-455
11. Chakravarti A. Population genetics-making sense out of sequence. Nat. Genet. 21 (1999) 56-60
12. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 25 (2003) 115-121
13. Geyer M.A., and Vollenweider F.X. Serotonin research: contributions to understanding psychoses. Trends Pharmacol. Sci. 29 (2008) 445-453
14. Ginawi O.T., Al-Majed A.A., Al-Suwailem A.K., and El-Hadiyah T.M. Involvement of some 5-HT receptors in methamphetamine-induced locomotor activity in mice. J. Physiol. Pharmacol. 55 (2004) 357-369
15. Hashimoto T., Kitamura N., Kajimoto Y., Shirai Y., Shirakawa O., Mita T., Nishino N., and Tanaka C. Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology (Berl) 112 (1993) S35-S39
16. Hashimoto T., Nishino N., Nakai H., and Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48 (1991) 355-363
17. Hong C.J., Chen T.J., Yu Y.W., and Tsai S.J. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 6 (2006) 27-33
18. Huang Y.Y., Battistuzzi C., Oquendo M.A., Harkavy-Friedman J., Greenhill L., Zalsman G., Brodsky B., Arango V., Brent D.A., and Mann J.J. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int. J. Neuropsychopharmacol. 7 (2004) 441-451
19. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Inada T., and Ozaki N. Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol. Psychiatry 56 (2004) 698-700
20. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshiya Y., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., and Ozaki N. Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int. J. Neuropsychopharmacol. 9 (2006) 77-81
21. Kishi T., Ikeda M., Kitajima T., Suzuki T., Yamanouchi Y., Kinoshita Y., Kawashima K., Ozaki N., and Iwata N. No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B (2008) 531-534
22. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Iyo M., Sora I., Sekine Y., Ozaki N., Ujike H., and Iwata N. Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population. Ann. NY Acad. Sci. 1139 (2008) 63-69
23. Kishi T., Kitajima T., Ikeda M., Yamanouchi Y., Kinoshita Y., Kawashima K., Okochi T., Okumura T., Tsunoka T., Inada T., Ozaki N., and Iwata N. Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur. Arch. Psychiatry Clin. Neurosci. 259 (2009) 293-297
24. Kishi T., Kitajima T., Ikeda M., Yamanouchi Y., Kinoshita Y., Kawashima K., Okochi T., Ozaki N., and Iwata N. Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. Neurosci. Res. 62 (2008) 211-215
25. Kraus M.R., Al-Taie O., Schafer A., Pfersdorff M., Lesch K.P., and Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 132 (2007) 1279-1286
26. Le Francois B., Czesak M., Steubl D., and Albert P.R. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 55 (2008) 977-985
27. Lemonde S., Du L., Bakish D., Hrdina P., and Albert P.R. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int. J. Neuropsychopharmacol. 7 (2004) 501-506
28. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., Sequeira A., Kushwaha N., Morris S.J., Basak A., Ou X.M., and Albert P.R. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J. Neurosci. 23 (2003) 8788-8799
29. Mason S.L., and Reynolds G.P. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur. J. Pharmacol. 221 (1992) 397-398
30. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
31. Meltzer H.Y., and Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?. Behav. Brain Res. 195 (2008) 98-102
32. Millan M.J., and Colpaert F.C. Methylenedioxymethamphetamine induces spontaneous tail-flicks in the rat via 5-HT1A receptors. Eur. J. Pharmacol. 193 (1991) 145-152
33. Mossner R., Schuhmacher A., Kuhn K.U., Cvetanovska G., Rujescu D., Zill P., Quednow B.B., Rietschel M., Wolwer W., Gaebel W., Wagner M., and Maier W. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet. Genomics 19 (2009) 91-94
34. Neale B.M., and Sham P.C. The future of association studies: gene-based analysis and replication. Am. J. Hum. Genet. 75 (2004) 353-362
35. Neff C.D., Abkevich V., Packer J.C., Chen Y., Potter J., Riley R., Davenport C., DeGrado Warren J., Jammulapati S., Bhathena A., Choi W.S., Kroeger P.E., Metzger R.E., Gutin A., Skolnick M.H., Shattuck D., and Katz D.A. Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression. Mol. Psychiatry 14 (2009) 621-630
36. Parsey R.V., Olvet D.M., Oquendo M.A., Huang Y.Y., Ogden R.T., and Mann J.J. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 31 (2006) 1745-1749
37. Purcell S., Cherny S.S., and Sham P.C. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19 (2003) 149-150
38. Reynolds G.P., Arranz B., Templeman L.A., Fertuzinhos S., and San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am. J. Psychiatry 163 (2006) 1826-1829
39. Riad M., Garcia S., Watkins K.C., Jodoin N., Doucet E., Langlois X., el Mestikawy S., Hamon M., and Descarries L. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol. 417 (2000) 181-194
40. Sato M., Numachi Y., and Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr. Bull. 18 (1992) 115-122
41. Serretti A., Artioli P., Lorenzi C., Pirovano A., Tubazio V., and Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int. J. Neuropsychopharmacol. 7 (2004) 453-460
42. Serretti A., Mandelli L., Giegling I., Schneider B., Hartmann A.M., Schnabel A., Maurer K., Moller H.J., and Rujescu D. HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (2007) 291-299
43. Simpson M.D., Lubman D.I., Slater P., and Deakin J.F. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol. Psychiatry 39 (1996) 919-928
44. Sotelo C., Cholley B., El Mestikawy S., Gozlan H., and Hamon M. Direct immunohistochemical evidence of the existence of 5-HT1A autoreceptors on serotoninergic neurons in the midbrain raphe nuclei. Eur. J. Neurosci. 2 (1990) 1144-1154
45. Strobel A., Gutknecht L., Rothe C., Reif A., Mossner R., Zeng Y., Brocke B., and Lesch K.P. Allelic variation in 5-HT1A receptor expression is associated with anxiety- and depression-related personality traits. J. Neural Transm. 110 (2003) 1445-1453
46. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., Jayathilake K., and Meltzer H.Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry 158 (2001) 1722-1725
47. Sumiyoshi T., Park S., Jayathilake K., Roy A., Ertugrul A., and Meltzer H.Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 95 (2007) 158-168
48. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., and Meltzer H.Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708 (1996) 209-214
49. Varnas K., Halldin C., and Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum. Brain Mapp. 22 (2004) 246-260
50. Wang L., Fang C., Zhang A., Du J., Yu L., Ma J., Feng G., Xing Q., and He L. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J. Psychopharmacol. 22 (2008) 904-909
51. Weickert C.S., Miranda-Angulo A.L., Wong J., Perlman W.R., Ward S.E., Radhakrishna V., Straub R.E., Weinberger D.R., and Kleinman J.E. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum. Mol. Genet. 17 (2008) 2293-2309
52. Yu Y.W., Tsai S.J., Liou Y.J., Hong C.J., and Chen T.J. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur. Neuropsychopharmacol. 16 (2006) 498-503